IBEX Technologies Inc. (TSX:IBT), an innovator in the development of diagnostics and therapeutics for the management of cancer and arthritis, today announced that the European Patent Office has given notice of allowance of the human kallikrein 15 (hK15) patent, which is licensed to IBEX from Mt. Sinai Hospital (Toronto).
